{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', '7. The subject must have at least 2 HAE attacks which meet all of the requirements below', 'during the run-in period of a maximum of 56 days from the Screening visit:', 'The attacks are unique, which is defined as an attack that does not begin within', '48 hours of the end of a previous attack.', 'The attacks must have either been treated, required medical attention or be', 'documented to cause functional impairment based on subject entry in the diary.', 'Functional impairment is defined as the subject being unable to perform their', 'daily activities without restriction (ie, subject records that they are at least slightly', 'restricted in their daily activities during their HAE attack).', 'The attacks must include symptoms of swelling. Symptoms of swelling, in', 'addition to visible swelling, may also include symptoms in the oropharyngeal or', 'abdominal regions which are indicative of internal swelling.', 'The attacks are confirmed by the Investigator to be HAE attacks. Subjects will be', 'contacted within 2 business days of the attack to discuss the attack, any queries on', 'the entered data in the e-diary, as applicable.', 'Subjects who have recorded 2 such attacks may be randomized to study drug', 'beginning on or after Day 28 of the run-in period; subjects who have recorded', 'at least 3 such attacks may be randomized to study drug beginning on or after', 'Day 14 of the run-in period. Under no circumstances should the run-in attack', 'requirement for eligibility be disclosed to study subjects.', '8. Female subjects must meet at least 1 of the following requirements:', 'a. Be a woman of childbearing potential (defined as a nonmenopausal adult or', 'adolescent female who has not had a hysterectomy, bilateral oophorectomy, or', 'documented ovarian failure) who agrees to use at least an acceptable effective', 'contraceptive method during the study and for a duration of 30 days after last dose of', 'study drug. One or more of the following methods are acceptable:', 'Surgical sterilization (ie, bilateral tubal occlusion or vasectomy of male partner).', 'Placement of an intrauterine device (IUD) or intrauterine system (IUS) (implanted', 'any time prior to or during screening).', 'Progesterone-only (implantable or injectable only) or oral (norethindrone-based', 'only) hormonal contraception associated with inhibition of ovulation initiated at', 'least 7 days prior to the screening visit. Note: Desogestrel is not permitted during', 'this study.', 'Combined (estrogen and progestogen containing) oral, intravaginal, or', 'transdermal hormonal contraception associated with inhibition of ovulation.', 'Male or female condom with or without spermicide.', 'Use of an occlusive cap (diaphragm, or cervical/vault caps) with spermicide', '(foam/gel/film/cream/suppository).', 'Female subjects who report being postmenopausal for 2 years and have a', 'follicle-stimulating hormone (FSH) < 40 mIU/mL must agree to use at least an', '41']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'acceptable effective contraceptive method and (as proposed above) during study and', 'for 30 days after the last dose of study drug.', 'Female subjects of childbearing potential who declare themselves as either sexually', 'abstinent or exclusively having female sexual partners do not need to use an', 'acceptable method of contraception. Abstinence in this study is defined as \"true', 'abstinence: when this is in line with the preferred and usual lifestyle of the subject.\"', 'b. Be a woman of nonchildbearing potential (defined as postmenopausal for > 2 years or', 'having an FSH > 40 mIU/mL if postmenopausal 2 years or have had a', 'hysterectomy, bilateral oophorectomy, or documented ovarian failure.', '9.', 'Male subjects must comply with the following requirements through the end of the', 'study:', 'a. Subjects with female partners of childbearing potential (defined as postmenopausal', 'VI 2 years or a nonmenopausal female who has not had a hysterectomy, bilateral', 'oophorectomy, or documented ovarian failure) must agree to utilize at least', '1 acceptably effective contraceptive method. At least 1 or more of the following', 'methods are acceptable:', 'Surgical sterilization (ie, vasectomy or bilateral tubal occlusion of a female', 'partner)', 'Placement of an IUD or IUS', 'Any form of hormonal contraception (oral, implantable, injectable, intravaginal,', 'or transdermal)', 'Use of a condom with or without spermicidal foam/gel/film/cream/suppository', \"Partner's use of an occlusive cap (diaphragm, or cervical/vault caps) with\", 'spermicidal (foam/gel/film/cream/suppository)', 'Male subjects who declare themselves as sexually abstinent are acceptable for the', 'purposes of this study. Abstinence in this study is defined as \"true abstinence: when this', 'is in line with the preferred and usual lifestyle of the subject.\"', 'Note: Contraception is no longer required for male subjects and their female partners', 'under Protocol Version 3.0.', '10. In the opinion of the Investigator, the subject is expected to adequately comply with all', 'required study procedures for the duration of the study. The subject must demonstrate', 'adequate compliance with all study procedures required from the screening visit through', 'randomization, including diary recording of HAE attacks beginning at the screening visit.', '8.2.2.', 'Exclusion Criteria', 'Subjects must meet none of the numbered exclusion criteria below to be eligible for participation', 'in this study. Medications prohibited for use during the study are addressed in Section 9.7.1.', '1. Any clinically significant medical or psychiatric condition or medical history that, in the', \"opinion of the Investigator or Sponsor, would interfere with the subject's ability to\", 'participate in the study or increases the risk to the subject by participating in the study.', '42']\n\n###\n\n", "completion": "END"}